Lupus Erythematosus, Systemic research hub
10 indexed studies · 6 currently recruiting
- recruitingPhase II and Phase III (Integrated)
(Synbiose-2 )Synergetic B-cell immunomodulation in SLE – 2 nd study
This study is testing whether combining two medicines, Benlysta and Truxima, can better control systemic lupus erythematosus (lupus). Researchers want to see if using both treatments together helps calm the immune system, prevents symptom flares, and protects vital organs like the kidneys over a two-year period.
Netherlands - recruitingPHASE3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
This study is looking at a new medicine called nipocalimab for adults with moderate to severe lupus. It compares nipocalimab to a dummy treatment (placebo) to see if it can help reduce inflammation and improve lupus symptoms.
United States · Argentina · Australia - enrolling by invitationPHASE3
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
This study looks at how safe and well a medication called cenerimod works over a long time (up to 3 years) for adults with lupus. Participants have already been in another study and will now receive cenerimod alongside their usual lupus treatments.
United States · Argentina · Brazil - recruiting
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)
This study looks into specific natural substances in the blood, called autoantibodies, in people with lupus. We want to understand how these substances might contribute to lupus symptoms and how they affect certain body processes, hoping to learn more about this condition.
France - active not recruitingPHASE2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
This study is testing a new cell therapy called CC-97540 for people with lupus and lupus kidney disease. It aims to see if it's safe and effective when other treatments haven't worked well enough.
United States · Argentina · Austria - recruiting
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
This study looks at how a medicine called anifrolumab works for adults with lupus (SLE) in real-life settings. We want to see how it affects their symptoms, quality of life, and overall health over two years.
Germany - recruitingPHASE1, PHASE2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
This study is testing a new treatment called AZD0120 for severe lupus (Systemic Lupus Erythematosus) that hasn't responded to other medicines. It aims to see if the treatment is safe, how well people tolerate it, and if it helps improve lupus symptoms in adults.
United States · Australia · Canada - active not recruitingPHASE2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
This study is testing a new cell therapy called rapcabtagene autoleucel for severe lupus (SLE) or lupus affecting the kidneys (lupus nephritis). It aims to see how well it works and if it's safe for people whose current treatments aren't effective.
United States · Argentina · Australia - active not recruitingPHASE3
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
This study is testing a new medicine, cenerimod, for people with a type of lupus called Systemic Lupus Erythematosus (SLE). It aims to see if adding cenerimod to current treatments helps reduce symptoms and is safe.
United States · Chile · Czechia - active not recruitingPHASE3
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
This study is testing a new injection, litifilimab, for adults with active lupus (SLE) who are already on standard treatments. Researchers want to see if it improves lupus symptoms and is safe over 52 weeks.
United States · Argentina · Belgium